Altesa secured a $75 million Series B to advance an antiviral program, with former HHS official Brett Giroir reported as a lead investor in the financing, according to BioCentury’s finance report. The funding is earmarked to push lead candidates through IND enabling and early clinical work. The round reflects investor appetite for antivirals following high‑profile pandemic preparedness priorities. Altesa’s financing underscores continued private capital flows into therapeutics focused on viral threats and supports expansion of preclinical-to‑clinical pipelines in infectious disease.